Starting on:
Mar 22, 2021
Ending on:
Mar 23, 2021
Moderator(s):
Venue:
THE KAREN HOSPITAL
Max Credits:
3 Points
Provider:
Karen Hospital
Claim Points
Mar 22, 2021
Ending on:
Mar 23, 2021
Moderator(s):
THE KAREN HOSPITAL
Max Credits:
3 Points
Provider:
Karen Hospital
Claim Points
JOURNAL CLUB - 23/03/2021
Starting on:
Mar 22, 2021 8:00 AM
Mar 22, 2021 8:00 AM
Ending on:
Mar 23, 2021 9:00 AM
Mar 23, 2021 9:00 AM
Venue:
THE KAREN HOSPITAL
THE KAREN HOSPITAL
Description
Dapagliflozin and Cardiovascular outcomes in type 2 diabetes - Declare. The DECLAREâ??TIMI 58 trial showed that dapagliflozin is superior to placebo in improving glycemic control and noninferior but not superior for reducing MACE in patients with DM2 and high CV risk.
Objectives
The goal of the trial was to assess the cardiovascular (CV) safety of dapagliflozin in patients with type 2 diabetes mellitus (DM2) and either established CV disease (CVD) or multiple risk factors.
Presenters
-
Dr.
JASON MUGA
MEDICAL OFFICER
THE KAREN HOSPITAL